We studied people with obesity involved in the SURMOUNT-1 trial of the dual GLP-1 and GIP receptor agonist, tirzepatide. People with pathogenic variants of the gene encoding the melanocortin 4 receptor (MC4R) lost a similar amount of weight to people with an intact gene, demonstrating that tirzepatide is effective in MC4R deficiency.